sitagliptin glp 1 agonist Glucagon-like peptide-1 glp-1 agonist dpp 4 inhibitor

Erratum in JAMA 2016, 315, 90

This is a mechanism no approved drug currently uses Phase 2 trials showed up to 24% body weight reduction over 48 weeks, meaningfully exceeding tirzepatide and semaglutide outcomes Phase 3 trials are currently underway

Multiorgan, multipathway effects

Accelerated Drug Discovery and Development Optimization of Formulations: AI algorithms can optimize drug formulations by analyzing vast datasets, including chemical structures and patient records, to identify the most effective formulations and dosing strategies for GLP-1 receptor agonists Identification of Novel Compounds: AI can help in identifying novel compounds, including plant-derived compounds, which could lead to new GLP-1 receptor agonists1